Skip to content

EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study

Combination of the EMDR Integrative Group Protocol and Individual EMDR Treatment in Patients With Advanced Thyroid Cancer: A Pilot Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07447089
Enrollment
25
Registered
2026-03-03
Start date
2025-12-05
Completion date
2026-12-05
Last updated
2026-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasm, Post-traumatic Stress Disorder (PTSD), Psychological Distress, Thyroid Neoplasms

Keywords

Psychoncology, Cancer

Brief summary

The main aim of the present process-outcome study is to evaluate the feasibility and the effects of an EMDR-IGTP-OTS group intervention on a sample of people with cancer, by using a process-outcome study design, with repeated measures.

Detailed description

The diagnosis of cancer represents a potentially life-threatening event that can be considered a unique traumatic stressor. A cancer diagnosis can disrupt a person's life, affecting emotions, cognition, and physical pain impacting the individual sense of identity. Findings from the literature suggest that EMDR can be a valid treatment in the processing of cancer-related traumatic events. With this proposal, the investigators aim to evaluate the feasibility and the effects of a combined EMDR Integrative Group Treatment Protocol and an optional EMDR individual protocol for people with cancer.

Interventions

BEHAVIORALEMDR-IGTP-OTS

The intervention follows the EMDR 8-phase protocol as indicated by Jarero et al. (2018). The group sessions use the IGTP-OTS (Integrative Group Treatment Protocol for Ongoing Traumatic Stress) to provide early stabilization.

Sponsors

Università Cattolica di Milano
Lead SponsorOTHER
ASST Santi Paolo e Carlo
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* cancer diagnosis * PTSD (IES-R \> 32)

Exclusion criteria

* receiving specialized trauma therapy * receiving current psychiatric pharmacological treatment, unless the dosage has been stable for at least 2 months prior to enrollment

Design outcomes

Primary

MeasureTime frameDescription
Impact of Event Scale-Revised (IES-R)Baseline (T1) and Post-intervention (T2, approximately 1 month), Follow-up (T3, approximately 3 month)Impact of Event Scale-Revised range: The scale is composed by 22 items, each scored 0-4 (Min Score: 0; Max Score: 88). A higher score indicates a higher intensity of post-traumatic stress symptoms

Countries

Italy

Contacts

CONTACTCesare Cavalera
cesarem.cavalera@unicatt.it+393409373408

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026